Sign In
Buy ALBO
$44.15
+0 (+0%)
At Close: May 26, 2023
Albireo Pharma: De-Risked Small-Cap Biotech Ready For Commercialization
09:07am, Monday, 25'th Jan 2021
Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications. The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasis (PFIC)
Albireo Recognizes International Alagille Syndrome Awareness Day 2021
08:30am, Friday, 22'nd Jan 2021
Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases Albireo supports the Alagille syndrome community to advoc
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 14'th Jan 2021
BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducemen
Albireo to Host Virtual Investor Commercial Day 2021
08:30am, Thursday, 07'th Jan 2021
BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a vi
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 06'th Jan 2021
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducemen
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 11'th Dec 2020
BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant
Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC
04:30pm, Tuesday, 08'th Dec 2020
- Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients -
New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease
08:05am, Friday, 13'th Nov 2020
- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus -
Albireo Reports Q3 2020 Financial Results and Provides Business Update
07:30am, Thursday, 05'th Nov 2020
- P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 -
Albireo's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
07:27am, Friday, 11'th Sep 2020
Albireo reports positive data from Phase 3 trial. Jazz Pharmaceuticals inks new cancer deal with Redx Pharma.
Albrireo Therapeutics (ALBO) Investor Presentation - Slideshow
05:18pm, Friday, 28'th Aug 2020Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
06:10pm, Friday, 21'st Aug 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Albireo Pharma
Albireo Down on Unimpressive Data From Mid-Stage NASH Study
02:17pm, Wednesday, 19'th Aug 2020
Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH
08:40pm, Tuesday, 18'th Aug 2020
‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒BOSTON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (N
